

Effect of Serum IL-1 β of PCSO-524 and Firocoxib in Dogs Undergoing Medial Patellar Luxation Repair

Sarat Kongwut¹ Kumpanart Soontornvipart^{1*} Meena Sarikaphuti² Pussadee Makoom³

Korakot Nganvongpanit⁴

Abstract

Thirty client-owned Pomeranians, between one and seven years old that had grade-three medial patellar luxation, were enrolled in this experiment. The dogs did not have other diseases. All the dogs received the same physical and clinical orthopaedic examinations, as well as the peak vertical force gait analysis, radiographic examination for assessment of bone deformities. Then, blood was collected from each dog for evaluation of complete blood counts (CBCs), blood chemistry and biomarker assays (IL-1 β) before surgery. After surgery to correct their medial patellar luxations, they were divided into three groups by random sampling. The first group received only Firocoxib (5 mg/kg once daily). The second group received only PCSO-524 (10 mg/kg, twice daily). The third group received Firocoxib (5 mg/kg, once daily) combined with PCSO-524 (10 mg/kg, twice daily). Treatment finished at the end of the second week. Every dog received a blood collection before surgery and at days one, five and 14 after surgery. IL-1 β concentrations in serum were determined by commercially available canine ELISA kits. The result was that two treatments (Firocoxib only and Firocoxib combined with PCSO-524) can reduce the serum IL-1 β level by day 14 after the surgical correction of patellar luxation. However, the group that received PCSO-524 did not have significantly decreased of serum IL-1 β , but it had a slower decline of the serum IL-1 β level. We concluded that PCSO-524 did not diminish serum IL-1 β levels as good as NSAID in case of post-surgical correction of patellar luxation. For the further study, we recommend to increase dose of PCSO-524 and period of treatment before surgery in other condition that causes acute inflammation. Maybe the extraction of active ingredients in PCSO-524 is necessary. Moreover, we suggest increasing the sample size for showing the more significance and accurate results.

Keywords: acute inflammation, dog, Interleukin 1, patellar luxation, PCSO-524

¹Department of Veterinary Surgery, Faculty of Veterinary Medicine, Chulalongkorn University, Bangkok 10330, Thailand

²Biochemistry Unit, Department of Physiology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok 10330, Thailand

³Animal Disease Laboratory, Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok 10330, Thailand

⁴Department of Veterinary Preclinical Science, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand

*Correspondence: skumpana@gmail.com

Introduction

PCSO-524 is extracted from the New Zealand green-lipped mussel and is a popular nutraceutical agent for use in humans. It contains mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are classed as omega 3 polyunsaturated fatty acids (Sinclair et al., 2000). Many researches have shown that PCSO-524 can reduce pain and the progression of joint diseases such as rheumatoid arthritis and osteoarthritis in humans (Lau et al., 2004; Brien et al., 2008; Coulson et al., 2012). In dogs, PCSO-524 improves clinical signs of osteoarthritis and degenerative spinal diseases (Mongkon and Soontornvipart, 2012). The mechanism of this agent is inhibition of membrane arachidonic acid metabolism by blocking 5-lipoxygenase (LOX), which causes the formation of leukocyte B4 (LTB4) by polymorphonuclear cells (PMN) in vitro (Halpern, 2000). PCSO-524 also inhibits prostaglandin E2 (PGE2) production and thromboxane by inhibiting cyclooxygenase (COX) pathways (McPhee et al., 2007). Prostaglandin and thromboxane play the major role in the progression of cartilage degeneration.

Inflammation has an important role in pathogenesis and in clinical signs of joint diseases in both humans and animals. Many studies interpreted results from physical examinations, radiography, anthropometric measurements or assessments from patients (Lau et al., 2004; Brien et al., 2008; Coulson et al., 2012), while some studies measured the biomarkers (Murphy et al., 2006). Errors from physical examination, radiography, anthropometric measurement and assessment may be possible. The accuracy of data is an important factor in research, thus the measurement of biomarkers, the objective data, is more reliable. In human, IL-1 is a popular biomarker to detect joint inflammation. IL-1 plays an important role in bone loss in patients with rheumatoid arthritis (Dinarello, 2011). In addition, there are many studies showing that IL-1 is correlated with other diseases such as Alzheimer disease and cancer in human (Lewis et al., 2006; Shaftel et al., 2008). The study by Assuma and coworker in 1998 revealed that IL-1 antagonist can inhibit inflammatory response, by decreasing the recruitment of mononuclear cells, and bone loss in *Macaca fascicularis* with experimental periodontitis (Assuma et al., 1998). Another study found that IL-1 β may be possible biomarker for detection of early stages of inflammation in dogs (Prachar et al., 2013).

PCSO-524 had been studying for controlling chronic inflammation in many diseases such as osteoarthritis or rheumatoid arthritis (Lau et al., 2004; Hurst et al., 2010; Coulson et al., 2012; Zawadzki et al., 2013). There are many researches supporting that PCSO-524 has good effect with this disease. However, there are just a few of the studies of PCSO-524 with acute inflammation. This is the first study of relation between using PCSO-524 and IL-1 β , which is the inflammation-related biomarker in blood. The model of acute inflammation in this study is surgical correction of patellar luxation which we found mostly in orthopedic clinic. If PCSO-524 can reduce IL-1 β as good as (or better than) NSAIDs, resulting in a reduction in the use of NSAIDs which generates more side-effects. Moreover, if PCSO-524 can inhibit acute inflammation, therefore a decrease in development from acute to chronic inflammation, can be possible.

The objective of this study was to compare the serum IL-1 β levels in dogs undergoing patellar luxation surgery which is treated with PCSO-524, the extract from New Zealand Green-lipped mussel (*Perna canaliculus*) and/or Firocoxib.

Materials and Methods

Animal: Thirty client-owned Pomeranians, between one and seven years old (3 ± 2.4 years) that had grade-three medial patellar luxation were enrolled in this experiment. The inclusion criteria were grade-three patellar luxation, no history of treatment for patellar luxation, no other diseases (eg. heart disease, skin disease) and normal blood results. Exclusion criteria were having other diseases, or an inability to receive drugs continuously.

Informed owner consent was gained and the research protocol was approved by the Faculty of Veterinary Sciences Ethics Committee, Chulalongkorn University, Bangkok, Thailand.

Pretreatment evaluation: All the dogs received the physical and clinical orthopaedic examinations and radiographic examinations (hip and stifle joints) to assess bone deformities. Three milliliters of blood was collected from each dog so that complete blood counts (CBCs), blood chemistry and biomarker assays (IL-1 β) could be performed.

Table 1 Drugs using in anesthesia for surgery

	Drug	Concentration	Dose	Route
Premedication	Acepromazine	1 mg/ml	0.03 mg/kg	Intramuscular
	Morphine	10 mg/ml	0.5 mg/kg	(combined)
Induction	Propofol	10 mg/ml	4 mg/kg	Intravenous
Maintainance	Isoflurane	-	1-2 mg%	Inhalation
Antibiotics	Cefazolin	250 mg/ml	25 mg/kg	Intravenous
Post-operative drug	Tramadol	50 mg/ml	4 mg/kg	Subcutaneous

Treatment procedure: All dogs had an anesthesia protocol (Table 1) and received surgical treatment for the correction of patellar luxation by the same veterinary surgeon, that used three techniques (medial desmotomy, lateral imbrication and throclear block

recession) to correct medial patellar luxation. In the next day after surgery, they divided into 3 groups by random sampling. The first group received only Firocoxib (5 mg/kg once daily). The second group received only PCSO-524 (10 mg/kg, twice daily). The

third group received Firocoxib (5 mg/kg, once daily) combining with PCSO-524 (10 mg/kg, twice daily). Treatment finished at the end of the 2nd week.

Parameter, monitoring and blood collection: Every dog received a physical examination, an orthopaedic examination, a clinical scoring system, gait analysis and a pain-scoring system (Glasgow pain scale) by the same veterinarian before surgery and at days one, five and 14 after surgery. If the pain scale is more than 14, the dog was excluded from this research and relieved pain upon the veterinarian's decision immediately. Three milliliters of blood samples were collected from the cephalic vein or saphenous vein of each dog. One milliliter was separated into two tubes for complete blood counts (CBCs) and blood chemistry tests. The samples for CBCs were kept in anticoagulant 100IU/ml heparin (APSFInchem, Australia). The samples for blood chemistry were kept in plain tubes that did not contain anticoagulant. These samples were kept at 4°C. The other two milliliters of blood samples (for biomarker assays) were kept in plain tubes without anticoagulant and centrifuged at 7,000xg for 15 min to obtain serum, then stored at -20°C until a batch analysis was performed.

Chemical substances' preparation and ELISA technique of IL-1 β : IL-1 β concentration in serum will be determined by a commercially available canine ELISA kit. The IL-1 β ELISA kit (USCN life Science Inc., China) has a minimum detectable dose that is typically less than 3.1pg/mL and a detection range of 7.81-500pg/mL. The microtiter plate has been

pre-coated with monoclonal antibody to canine IL-1 β . Canine serum and Biotin-conjugated antibody specific to canine IL-1 β were added to the wells consecutively. Therefore, Avidin conjugated to Horseradish Peroxidase (HRP) was added to each well and incubated. After TMB substrate solution addition, only wells that contain IL-1 β , Biotin-conjugated antibody and enzyme-conjugated Avidin showed a change in color. The enzyme-substrate reaction was terminated by addition of sulphuric acid solution. Finally, the color change was measured spectrophotometrically at a wavelength of 450 nm.

Statistical analysis: All data expressed as mean $\pm$ SD. Parameters in group compared using repeated measure ANOVA (analysis of variance). Parameters between group compared by one-way ANOVA. P-values of <0.05 considered to be statistically significant. All data use SPSS programme to analyse.

Results and Discussion

There was no significance of serum IL-1 level in 3 groups of treatment during 5 times of data collection. In all groups, serum IL-1 β level increases in day 1 after surgery. In group 1 and 3, serum IL-1 β level decreases significantly in day 14 after surgery comparing day 1 and 5 after surgery (*), respectively. In group 2, serum IL-1 β level slightly decreased since day 5 after surgery. However, there is no significantly difference of the value between day 1 and day 14 after surgery (Fig 1).




Figure 1 Graph of serum IL-1 β levels

This study show that two treatments (Firocoxib only and Firocoxib combined with PCSO-524) can reduce the serum IL-1 β level by day 14 after the surgical correction of patellar luxation. However, the group that received PCSO-524 did not have significantly decreased of serum IL-1 β , but it had a slower decline of the serum IL-1 β level compared with the other treatments. This result did not relate with the

study by Singh et al. (2008), which reported that PCSO-524 can reduces acute inflammation. Their experiment indicated that the administration of crude lipid extract CO₂-SFE and a free-fatty-acid extract from *Perna canaliculus* for five days was equipotent to the ability of Piroxicam to reduce inflammation in adjuvant-induced arthritis in rats (Singh et al., 2008).

In conclusion, PCSO-524 did not diminish serum IL-1 β levels as good as NSAID in case of post-surgical correction of patellar luxation. For the further study, we recommend to increase dose of PCSO-524 and period of treatment before surgery in other condition that causes acute inflammation. Maybe the extraction of active ingredients in PCSO-524 is necessary. Moreover, we suggest increasing the sample size for showing the more significance and accurate results.

Acknowledgements

The Scholarship from the Graduate School, Chulalongkorn University to commemorate the 72nd anniversary of his Majesty King Bhumibala Aduladeja is gratefully acknowledged. This research is also supported by the 90th Anniversary of Chulalongkorn University, Rachadapisek Sompote Fund.

References

- Assuma R, Oates T, Cochran D, Amar S and Graves DT 1998. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. *J Immunol.* 160(1): 403-409.
- Brien S, Prescott P, Coghlan B, Bashir N and Lewith G 2008. Systematic review of the nutritional supplement Perna Canaliculus (green-lipped mussel) in the treatment of osteoarthritis. *Qjm.* 101(3): 167-179.
- Coulson S, Vecchio P, Gramotnev H and Vitetta L 2012. Green-lipped mussel (*Perna canaliculus*) extract efficacy in knee osteoarthritis and improvement in gastrointestinal dysfunction: a pilot study. *Inflammopharmacology.* 20(2): 71-76.
- Dinarelli CA 2011. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. *Blood.* 117(14): 3720-3732.
- Halpern GM 2000. Anti-inflammatory effects of a stabilized lipid extract of *Perna canaliculus* (Lyprinol). *Allerg Immunol (Paris).* 32(7): 272-278.
- Hurst S, Zainal Z, Caterson B, Hughes CE and Harwood JL 2010. Dietary fatty acids and arthritis. *Prostaglandins Leukot Essent Fatty Acids.* 82(4-6): 315-318.
- Lau C, Chiu P, Chu E, Cheng I, Tang W, Man R and Halpern G 2004. Treatment of knee osteoarthritis with Lyprinol®, lipid extract of the green-lipped mussel-A double-blind placebo-controlled study. *Progress in Nutrition.* 6(1): 17-31.
- Lewis AM, Varghese S, Xu H and Alexander HR 2006. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. *J Transl Med.* 4: 48.
- McPhee S, Hodges LD, Wright PF, Wynne PM, Kalafatis N, Harney DW and Macrides TA 2007. Anti-cyclooxygenase effects of lipid extracts from the New Zealand green-lipped mussel, *Perna canaliculus*. *Comp Biochem Physiol B Biochem Mol Biol.* 146(3): 346-356.
- Mongkon N and Soontornvipart K 2012. Preliminary Study of the Clinical Outcome of Using PCSO-524 Polyunsaturated Fatty Acid Compound in the Treatment of Canine Osteoarthritis and Degenerative Spinal Diseases. *Thai J Vet Med.* 42(3): 311-317.
- Murphy KJ, Galvin K, Kiely M, Morrissey PA, Mann NJ and Sinclair AJ 2006. Low dose supplementation with two different marine oils does not reduce pro-inflammatory eicosanoids and cytokines in vivo. *Asia Pac J Clin Nutr.* 15(3): 418-424.
- Prachar C, Kaup F-J and Neumann S 2013. Interleukin-1 Beta (IL-1 β) in the Peripheral Blood of Dogs as a Possible Marker for the Detection of Early Stages of Inflammation. *Open Journal of Veterinary Medicine.* 3(07): 302.
- Shaftel SS, Griffin WS and O'Banion MK 2008. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. *J Neuroinflammation.* 5: 7.
- Sinclair AJ, Murphy KJ and Li D 2000. Marine lipids: overview "news insights and lipid composition of Lyprinol". *Allerg Immunol (Paris).* 32(7): 261-271.
- Singh M, Hodges L, Wright P, Cheah D, Wynne P, Kalafatis N and Macrides T 2008. The CO 2-SFE crude lipid extract and the free fatty acid extract from *Perna canaliculus* have anti-inflammatory effects on adjuvant-induced arthritis in rats. *Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology.* 149(2): 251-258.
- Zawadzki M, Janosch C and Szechinski J 2013. *Perna canaliculus* Lipid Complex PCSO-524™ Demonstrated Pain Relief for Osteoarthritis Patients Benchmarked against Fish Oil, a Randomized Trial, without Placebo Control. *Mar Drugs.* 11(6): 1920-1935.

บทคัดย่อ

ผลของสารสกัดจากหอยแมลงภู่นิวซีแลนด์และ Firocoxib ต่ออินเตอร์ลิวคิน 1 เบต้า ในซีรัมของสุนัขที่ได้รับการผ่าตัดแก้ไขสะบ้าเคลื่อน

ศรารัตน์ คงวุธ¹ กัมปนาท สุนทรวิภาต^{1*} มีนา สาริกะภูติ² ศุภศติ มาคุ้ม³ กรกฎ งานวงศ์พาณิชย์⁴

สุนัขพันธุ์ปอมเมอเรเนียน อายุ 1-7 ปี ไม่จำกัดเพศ ไม่มีปัญหาสุขภาพอื่นๆ นอกจากมีภาวะลูกสะบ้าเคลื่อนระดับ 3 จำนวน 30 ตัว จะได้รับการตรวจร่างกายทั่วไป, ตรวจทางออร์โธปิดิกส์, ตรวจการเดิน, การลงน้ำหนัก และ ตรวจเลือดหาสารสื่ออักเสบในเลือด (IL-1 β) ก่อนเข้ารับการผ่าตัดแก้ไขลูกสะบ้าเคลื่อน หลังการผ่าตัด สุนัขทั้งหมดจะถูกสุ่มแบ่งออกเป็น 3 กลุ่ม กลุ่มละ 10 ตัว ได้รับการรักษาเป็นระยะเวลา 14 วันติดต่อกัน โดยกลุ่มแรกจะได้รับยา Firocoxib ปริมาณ 5 มก.ต่อกก. วันละ 1 ครั้ง กลุ่มที่สองจะได้รับสาร PCSO-524 ปริมาณ 1 แคปซูล วันละ 2 ครั้ง และกลุ่มสามจะได้รับยา Firocoxib ปริมาณ 5 มก.ต่อกก. วันละ 1 ครั้ง ร่วมกับสาร PCSO-524 ปริมาณ 1 แคปซูล วันละ 2 ครั้ง ทำการตรวจเลือดหาสารสื่ออักเสบในเลือด (IL-1 β) ในวันที่ 1, 5 และ 14 ภายหลังการผ่าตัด ผลปรากฏว่ากลุ่มที่ได้รับยา Firocoxib และกลุ่มที่ได้รับยา Firocoxib ร่วมกับ PCSO-524 มีปริมาณ IL-1 β ที่ลดลงในวันที่ 14 ภายหลังการผ่าตัดอย่างมีนัยสำคัญทางสถิติ แต่กลุ่มที่ให้สาร PCSO-524 อย่างเดียวนั้น ถึงแม้ว่าจะสามารถลดปริมาณ IL-1 β ได้แต่ไม่มีความแตกต่างอย่างมีนัยสำคัญทางสถิติ สรุปได้ว่า PCSO-524 ไม่สามารถลดปริมาณ IL-1 β ในกระแสเลือดได้เทียบเท่ากับ Firocoxib ในสุนัขที่ได้รับการผ่าตัดแก้ไขสะบ้าเคลื่อน อย่างไรก็ตามการศึกษาค้นคว้าของ PCSO-524 ต่อภาวะอักเสบแบบเฉียบพลันนั้นยังมีไม่มากนักในปัจจุบัน ทางผู้วิจัยจึงแนะนำให้เพิ่มปริมาณการใช้ PCSO-524 และควรมีการให้ยาก่อนการผ่าตัด รวมถึงการศึกษาค้นคว้าของ PCSO-524 ในกรณีอื่นที่มีการอักเสบแบบเฉียบพลัน และการเพิ่มขนาดของกลุ่มตัวอย่างจึงเป็นที่น่าสนใจในการศึกษาต่อไปในอนาคต

คำสำคัญ: การอักเสบแบบเฉียบพลัน สุนัข อินเตอร์ลิวคิน 1 ภาวะสะบ้าเคลื่อน สารสกัดจากหอยแมลงภู่นิวซีแลนด์

¹ภาควิชาสัตวศาสตร์ คณะสัตวแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย ถนนอังรีดูนังต์ เขตปทุมวัน กรุงเทพฯ 10330

²หน่วยชีวเคมี ภาควิชาสรีรวิทยา คณะสัตวแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย ถนนอังรีดูนังต์ เขตปทุมวัน กรุงเทพฯ 10330

³หน่วยชันสูตรโรคสัตว์ ภาควิชาพยาธิวิทยา คณะสัตวแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย ถนนอังรีดูนังต์ เขตปทุมวัน กรุงเทพฯ 10330

⁴สาขาวิชาฟิสิกส์คลินิกทางสัตวแพทย์ คณะสัตวแพทยศาสตร์ มหาวิทยาลัยเชียงใหม่ ถนนคันคลองชลประทาน อำเภอเมือง จังหวัดเชียงใหม่ ประเทศไทย 50100

*ผู้รับผิดชอบบทความ E-mail: skumpana@gmail.com